Poster Presentation ANZBMS-MEPSA-ANZORS 2022

Atypical anecdotes: three cases of stress fracture associated with denosumab use for osteoporosis (#230)

Caitlin Corkhill 1 , Sonia Stanton 1
  1. The Canberra Hospital, Garran, ACT, Australia

Atypical fractures are a rare adverse skeletal outcome of antiresorptive treatment and predominantly associated with long-term bisphosphonate use(1-3). Highest incidence occurs with long-term (>8yrs) alendronate use at ~13 per 10,000 patient-years, but drops by >50% one year and >80% three years after ceasing bisphosphonate(2). Published cases have been associated with denosumab, most with extensive prior bisphosphonate exposure(2-8), with fewer atypical fractures associated with denosumab involving very short-term bisphosphonate use(9,10). Five cases are reported in bisphosphonate-naïve patients taking denosumab(11-14).

The best characterised fracture type is atypical femur fracture (AFF) with specific radiological and clinical definition criteria(15). Atypical stress reactions of the femoral diaphysis and atypical or stress fractures at other sites, including periprosthetic, have also been associated with antiresorptives(4,16-18). Fractures meeting AFF criteria have additionally been reported in the absence of antiresorptive exposure(19-21), with additional risk factors including metabolic bone disorders, femur geometry (lateral bowing, varus hip alignment), inflammatory arthritis, glucocorticoid and proton-pump inhibitor (PPI) use(19).  

We describe a series of three patients with minimal-trauma atypical or stress fractures in the setting of denosumab use for osteoporosis, two of which occurred in the absence of prior bisphosphonate exposure and one with previous bisphosphonate use (Table 1). Common across the cases is relatively young age at treatment onset and no prior fracture. Two patients were mobile and active throughout their treatment. Two had body mass index >32kg/m2, and one had asymmetrical antalgic gait, which possibly contributed to fracture site mechanical loading. All had significant improvement in bone mineral density (BMD) measured around the time of fracture, which may suggest an exaggerated response to denosumab. However, as post-fracture bone density was performed on the contralateral femur in two cases, another postulation is of pre-existing significant between-hip variation in BMD, with mechanical asymmetry predisposing to atypical fracture.

629996cb7a792-Abstract+Table+1.jpg

 

  1. Starr J, Tay YKD, Shane E. Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures. Curr Osteoporos Rep. 2018 Aug;16(4):519-529.
  2. Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022 Mar 12;399(10329):1080-1092.
  3. Noble JA, McKenna MJ, Crowley RK. Should denosumab treatment for osteoporosis be continued indefinitely? Ther Adv Endocrinol Metab. 2021 Apr 22;12:20420188211010052.
  4. Dupaix JP, Opanova MI, Lee LSK, Christensen K. Denosumab-Associated Peri-Implant Atypical Femur Fracture: A Case Report. Hawaii J Health Soc Welf. 2019 Nov;78(11 Suppl 2):47-51.
  5. Drampalos E, Skarpas G, Barbounakis N, Michos I. Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop. 2014 Feb;85(1):3-5.
  6. Selga J, Nuñez JH, Minguell J, Lalanza M, Garrido M. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporos Int. 2016 Feb;27(2):827-32.
  7. Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab--a case report. Acta Orthop. 2014 Feb;85(1):6-7.
  8. Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab—a case report. Bone. 2014 Apr 1;61:44-7.
  9. Khow KS, Yong TY. Atypical femoral fracture in a patient treated with denosumab. Journal of Bone and Mineral Metabolism. 2015 May;33(3):355-8.
  10. Villiers J, Clark DW, Jeswani T, Webster S, Hepburn AL. An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol. 2013;2013:249872.
  11. Hamahashi K, Noguchi T, Uchiyama Y, Sato M, Watanabe M. Clinical Features and Outcomes of Bilateral Atypical Femoral Fractures. Case Rep Orthop. 2020 Jul 23;2020:8824756.
  12. Paparodis R, Buehring B, Pelley EM, Binkley N. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract. 2013 May-Jun;19(3):e64-8.
  13. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445–454.
  14. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523.
  15. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. Journal of bone and mineral research. 2014 Jan;29(1):1-23.
  16. Binkley N, Goel H, Shives E, Krueger D, Hare K. A probable atypical ulnar fracture in a man receiving denosumab. Bone. 2021 Feb;143:115726.
  17. Takahashi Y, Hatashita S, Shinden Y, Ito M, Kaneuchi Y, Hakozaki M, Konno S. Periprosthetic Fracture Resembling Atypical Femoral Fracture After Fixation With Retrograde Intramedullary Nail in Elderly Women: A Report of Two Cases. In Vivo. 2021 May-Jun;35(3):1837-1842.
  18. Tan J, Sano H, Poole K. Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide. BMJ Case Rep. 2019 Jul 23;12(7):e229366.
  19. Georgiadis GF, Begkas DG, Maniatis KA, Vasilakis AE, Chatzopoulos STD, Balanika AP. Atypical Femoral Fracture in a Patient without Bisphosphonate or Denosumab Exposure-A Case Report. J Orthop Case Rep. 2021 Oct;11(10):21-24.
  20. Szolomayer LK, Izuchukwu KI, Lindskog DM. Bilateral atypical femur fractures without bisphosphonate exposure. Skeletal Radiol. 2017;46:241–7.
  21. Tan SC, Koh SB, Goh SK, Howe TS. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporosis International. 2011 Jul;22(7):2211-2.